Translational Medicine: Application of Omics for Drug Target Discovery and Validation

Drug research and development is a long, expensive and risky process. The novel omics technologies (genomics, transcriptomics, proteomics and metabonomics) and systems biology have brought unprecedented abilities to screen cells at the gene, transcript, protein, metabolite and their interaction network level in searching of novel drug targets, elucidating the primary mechanism-of-action of a drug, understanding side effects in unanticipated off-target interaction, validating existing drug candidates and finding new potential therapeutic applications for an established drug, hence to facilitate the translation from bench to bedside. This chapter provides an overview of recent applications of various omics technologies and systems biology to drug development.

[1]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Keun,et al.  Application of metabonomics in drug development. , 2007, Pharmacogenomics.

[3]  A. D. De Marzo,et al.  Abnormal DNA methylation, epigenetics, and prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[4]  M. Gladwin,et al.  Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. , 2006, Kidney international.

[5]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[6]  T. Yip,et al.  ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. , 2007, Clinical chemistry.

[7]  Sean Ekins,et al.  A novel method for generation of signature networks as biomarkers from complex high throughput data. , 2005, Toxicology letters.

[8]  A. Biondi,et al.  Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform , 2008, Leukemia.

[9]  Xuewu Zhang,et al.  Mass spectrometry-based "omics" technologies in cancer diagnostics. , 2007, Mass spectrometry reviews.

[10]  Yi Guo,et al.  Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. , 2007, Cancer research.

[11]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[12]  E. Yim,et al.  Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. , 2005, Gynecologic oncology.

[13]  Jeffrey S Ross,et al.  Multigene predictors in early-stage breast cancer: moving in or moving out? , 2008, Expert review of molecular diagnostics.

[14]  B. Grosbois,et al.  Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[16]  R. Dean,et al.  Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model. , 2007, Journal of proteome research.

[17]  Ben van Ommen,et al.  Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. , 2003, Biochemical pharmacology.

[18]  F. Jiang,et al.  Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach , 2006, Oncogene.

[19]  P. Jannetto,et al.  Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation. , 2007, Clinical chemistry.

[20]  Commentary: Where and how could biomarkers be used in 2016 , 2006, The AAPS Journal.

[21]  Philippe Froguel,et al.  Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. , 2008, Human molecular genetics.

[22]  Yusuke Nakamura,et al.  Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. , 2002, Cancer research.

[23]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[24]  R. Goodacre Metabolomics of a superorganism. , 2007, The Journal of nutrition.

[25]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Robert P Tonge,et al.  Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  T. Yip,et al.  Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling , 2004, Clinical Cancer Research.

[28]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Xuewu Zhang,et al.  Biomarker validation: movement towards personalized medicine , 2007, Expert review of molecular diagnostics.

[30]  J. Dear,et al.  Liver proteomics for therapeutic drug discovery: Inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced acute renal failure* , 2007, Critical care medicine.

[31]  E. Davidov,et al.  Advancing drug discovery through systems biology. , 2003, Drug discovery today.

[32]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.

[33]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[34]  S. Mathoulin-Pélissier,et al.  Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. , 2006, Pharmacogenomics.

[35]  Thomas P Conrads,et al.  An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Huanwen Chen,et al.  Combining desorption electrospray ionization mass spectrometry and nuclear magnetic resonance for differential metabolomics without sample preparation. , 2006, Rapid communications in mass spectrometry : RCM.

[37]  M. Tomita,et al.  Differential Metabolomics Reveals Ophthalmic Acid as an Oxidative Stress Biomarker Indicating Hepatic Glutathione Consumption* , 2006, Journal of Biological Chemistry.

[38]  J. Griffiths,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.

[39]  Yingdong Zhao,et al.  Common cancer biomarkers. , 2006, Cancer research.

[40]  John C Lindon,et al.  Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. , 2004, Journal of pharmaceutical and biomedical analysis.

[41]  C. Huck,et al.  Biomarker discovery in breast cancer serum using 2‐D differential gel electrophoresis/ MALDI‐TOF/TOF and data validation by routine clinical assays , 2006, Electrophoresis.

[42]  F. Eckhardt,et al.  DNA methylation markers: a versatile diagnostic tool for routine clinical use. , 2007, Current opinion in molecular therapeutics.

[43]  R. Stephens,et al.  A Combined Proteome and Microarray Investigation of Inorganic Phosphate-induced Pre-osteoblast Cells*S , 2005, Molecular & Cellular Proteomics.

[44]  Götz Schlotterbeck,et al.  Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine. , 2006, Chemical research in toxicology.

[45]  Elaine Holmes,et al.  Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. , 2006, Journal of proteome research.

[46]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[47]  Rafael A Irizarry,et al.  Comprehensive high-throughput arrays for relative methylation (CHARM). , 2008, Genome research.

[48]  Ruili Huang,et al.  Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues , 2006, Molecular Cancer Therapeutics.

[49]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[50]  Feng Chen,et al.  Moving cancer diagnostics from bench to bedside. , 2007, Trends in biotechnology.